Brexpiprazole for schizophrenia and as adjunct for major depressive disorder
Por um escritor misterioso
Descrição
Efficacy of adjunctive brexpiprazole on the core symptoms of major depressive disorder: A post hoc analysis of two pooled clinical studies - ScienceDirect
Effects of adjunctive brexpiprazole on patient life engagement in major depressive disorder: Post hoc analysis of Inventory of Depressive Symptomatology Self-Report data - ScienceDirect
Brexpiprazole: A Newly Approved Atypical Antipsychotic Agent
Brexpiprazole in the Treatment of Major Depressive Disorder - Maryam I Al Shirawi, Nicole E Edgar, Sidney H Kennedy, 2017
Success and efficiency of phase 2/3 adjunctive trials for MDD funded by industry: a systematic review
Brexpiprazole for schizophrenia and as adjunct for major depressive disorder
Brexpiprazole in the Treatment of Major Depressive Disorder - Maryam I Al Shirawi, Nicole E Edgar, Sidney H Kennedy, 2017
Full article: Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study
Brexpiprazole for schizophrenia and as adjunct for major depressive disorder
Brexpiprazole - Mechanism of Action and Clinical Application
Mechanism of action of brexpiprazole: comparison with aripiprazole, CNS Spectrums
PDF] Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies
Example rapid review: Brexpiprazole for schizophrenia v2 –
Rexulti (Brexpiprazole) for the Treatment of Major Depressive Disorder (MDD) and Schizophrenia - Clinical Trials Arena
Effects of adjunctive brexpiprazole on sleep-wake and circadian parameters in youth with depressive disorders: study protocol for a clinical trial
